CLINICAL_TRIALS
trial_result
· 2023-03-02
Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH [Phase 2]
Summary
Phase 2 trial evaluating safety and efficacy of AK102, a PCSK9 inhibitor, in patients with homozygous familial hypercholesterolemia completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Akeso | Conditions: Homozygous Familial Hypercholesterolemia | Phase 2 | Status: COMPLETED